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ABSTRACT
The aim of this study was to prospectively assess 5-year health-related quality of life (HRQOL) of patients trea-
ted with carbon ion radiotherapy (C-ion RT) for clinically localized prostate cancer. A total of 417 patients
received carbon ion radiotherapy at a total dose of 63–66 Gray-equivalents (GyE) in 20 fractions over 5 weeks,
and neoadjuvant and adjuvant androgen deprivation therapy (ADT) were administered for intermediate and
high-risk patients. A HRQOL assessment was performed at ﬁve time points (immediately before the initiation of
C-ion RT, immediately after, and at 12, 36 and 60 months after completion of C-ion RT) using Functional
Assessment of Cancer Therapy (FACT) questionnaires. FACT-G and FACT-P scores were signiﬁcantly
decreased; however, the absolute change after 60 months was minimal. The transient decreases in the Trial
Outcome Index (TOI) score returned to their baseline levels. Use of ADT, presence of adverse events, and bio-
chemical failure were related to lower scores. Scores of subdomains of FACT instruments indicated characteristic
changes. The pattern of HRQOL change after C-ion RT was similar to that of other modalities. Further con-
trolled studies focusing on a HRQOL in patients with prostate cancer are warranted.
KEYWORDS: prostate cancer, carbon ion radiotherapy, quality of life, prospective study
INTRODUCTION
Deﬁnitive treatment modalities such as radical prostatectomy, exter-
nal beam radiotherapy (EBRT) and interstitial brachytherapy are
preferred for clinically localized prostate cancer. By using modern
radiotherapy modalities, such as intensity-modulated radiation ther-
apy, high-dose-rate (HDR) brachytherapy or charged particle radio-
therapy, hypofractionated and high-dose irradiation have become
available [1–4].
Unique characteristics of carbon ion beams, such as a high rela-
tive biological effectiveness (RBE) in Bragg peak, and higher linear
energy transfer (LET) than protons or photons, enable us to deliver
a sufﬁcient dose to the target volume, while minimizing the dose to
the surrounding normal tissues. In 1994, clinical trials using carbon
ion beams generated from the Heavy-Ion Medical Accelerator in
Chiba (HIMAC) were begun at the National Institute of
Radiological Sciences (NIRS). We started a Phase II study in 2000,
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and reported good clinical outcomes with a low incidence of toxici-
ties [5].
On the other hand, quality of life (QOL) is an important factor
in therapeutic decision-making for patients and is commonly used
as an end-point in clinical trials. Many studies for QOL assessment
have been carried out; however, few long-term prospective studies
have been reported.
In our Phase II study, QOL was investigated as a secondary end-
point. We previously reported the 12- and 36-month results of a
QOL assessment in prostate cancer with carbon ion radiotherapy
(C-ion RT), with a total dose of 63–66 GyE given in 20 fractions
over 5 weeks [6, 7]. In this article, we describe the results of our
trial at a follow-up of 5 years.
MATERIALS AND METHODS
Patients enrolled in a Phase II clinical study and those who received
the same treatment method as for the study of April 2000 to January
2007 were analyzed. Patients eligible for the study had a proven diag-
nosis of prostatic adenocarcinoma, localized Stage T1–3 cancer
according to the 1997 American Joint Committee on Cancer staging
system [8], and a primary tumor without radiologically detectable
involvement of regional lymph nodes or distant organs. All patients
were also required not to have undergone previous treatment
for prostate cancer except for hormone therapy. Patients with
T1/T2aN0M0, an initial prostate-speciﬁc antigen (iPSA) level of
<20 ng/ml, and a Gleason score (GS) of ≤6 were allocated to the
low-risk group, those with T3 or iPSA level ≥20 ng/ml or GS ≥ 8
were assigned to the high-risk group, and the remainder were assigned
to the intermediate-risk group [9]. All patients signed an informed
consent form approved by the local institutional review board.
Carbon ion radiotherapy
Patients were treated with C-ion beams generated by the HIMAC.
Details of the treatment protocol have been provided elsewhere
[9–11]. Brieﬂy, C-ion RT was performed once daily, 4 days per
week. Patients were treated with ﬁve ports, one anterior–posterior
port, a pair of lateral ports, and a second pair of lateral ports with a
reduced rectal ﬁeld [12]. One port was used in each session. The
irradiated dose was 63.0 or 66.0 Gy equivalents (GyE) in 20 frac-
tions, with a fraction dose of 3.15 or 3.3 GyE [5]. The patients
were hospitalized just before the start of C-ion RT and discharged
just after the end of the treatment.
Androgen deprivation therapy
Patients in both the intermediate- and high-risk groups received
androgen deprivation therapy (ADT) in combination with C-ion
RT. ADT was administered for a total duration of 6 months for
intermediate-risk patients and for more than 24 months for high-
risk patients. Neoadjuvant ADT was administered for 2–6 months
in both groups.
QOL questionnaire
The assessment of health-related quality of life (HRQOL) was per-
formed using the Functional Assessment of Cancer Therapy-General
(FACT-G) and for Prostate Cancer Patients (FACT-P) questionnaire
version 4 (Japanese version) [13].
The FACT-P, a validated questionnaire that has been frequently
used to assess QOL in men with clinically localized and advanced
prostate cancer, consists of the FACT-G questionnaire and the
Prostate Cancer Subscale (PCS). The FACT-G instrument is a self-
report questionnaire consisting of 27 question items, and it comprises
four subdomains: physical well-being (PWB), functional well-being
(FWB), social/family well-being (SFWB), and emotional well-being
(EWB). Each item is scored from 0 to 4, with a higher score repre-
senting a better QOL.
The prostate cancer subscale (PCS) contained in the FACT-P
consists of 12 questions particularly designed to measure the
HRQOL in patients with prostate cancer. The FACT-P score is the
combination of the four subdomains of the FACT-G and the PCS.
The Trial Outcome Index (TOI) is created by summing the PWB,
FWB, and PCS, and is considered to be a sensitive index focusing
on the physical aspects of HRQOL [14].
HRQOL assessment was prospectively performed at the follow-
ing ﬁve time points: before the initiation of C-ion RT, immediately
after, and 12 and 36 and 60 months after completion of C-ion RT.
The questionnaire sheet was given to each subject in person before
and immediately after C-ion RT, whereas the investigation was per-
formed by mail at 12, 36 and 60 months after C-ion RT.
Each subdomain score could be calculated if >50% of items
were answered.
The missing items, if any, were prorated from the answered
items. Subjects whose subscales were sufﬁcient to calculate each
index were used for analysis.
Follow-up
Patients were followed at 3-month intervals during the ﬁrst 5 years
after C-ion RT and at 3- to 6-month intervals thereafter. Late toxi-
cities caused by C-ion RT were scored according to Radiation
Therapy Oncology Group/European Organization for Research
and Treatment of Cancer (RTOG/EORTC) toxicity criteria [15].
The late reaction scores were recorded at each follow-up.
Biochemical failure (BF) was deﬁned according to the Phoenix cri-
teria [16].
Statistical analysis
Subdomains of the FACT-P and combined scores (FACT-G,
FACT-P, TOI) were tested by the paired t test using SPSS version
23 software (SPSS Inc., Chicago, IL). Those scores after C-ion RT
were compared with their baseline scores.
Subjects were divided by the presence of ADT, or any relapse or
late morbidities at each assessment time point to perform a subset
analysis between two subgroups. In the subgroup analysis, QOL
scores were analyzed using the unpaired t-test. Results were con-
sidered signiﬁcant at a P value of <0.05. The Bonferroni method
was used for adjustment for multiple comparisons.
RESULTS
A total of 417 males with prostate cancer were enrolled into the
Phase II study between April 2000 and January 2007 at NIRS.
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Patient characteristics are shown in Table 1. The median age was
69 years (ranging from 47 to 92 years). The clinical stage (accord-
ing to the 1997 UICC TNM classiﬁcation) was T1 in 109 subjects,
T2a in 87, T2b in 81, and T3 in 140. The Gleason score reassessed
by a central pathologist was ≤6 in 119 subjects, 7 in 183, and ≥8 in
115. The median pretreatment PSA was 14.0 ng/ml (ranging from
2.1 to 260 ng/ml). The numbers of patients classiﬁed into the low-,
intermediate- and high-risk groups were 79 (19%), 86 (21%) and
252 (60%), respectively. At 60 months after C-ion RT, 6 subjects
had died of prostate cancer and 17 had died of other diseases.
QOL questionnaire submission rate
The response rate of the QOL questionnaire and the number of
available data are also shown in Table 2. Overall, responses to
>90% of questions were available for calculating FACT-G, FACT-P
and TOI scores.
QOL scores
The means and standard deviations of the individual subdomains—
FACT-G, FACT-P and TOI—obtained from all subjects are shown
in Table 3 and Fig. 1 (see Supplementary Fig. 1).
In comparison with the corresponding baseline scores, a signiﬁ-
cant decrease was observed in PWB, PCS and TOI scores at com-
pletion of C-ion RT; however, these scores returned to the baseline
levels, and there was no signiﬁcant difference in the scores at base-
line and 60 months after C-ion RT. At 60 months after treatment
with C-ion RT, the SFWB, FACT-G and FACT-P scores remained
lower than the baseline levels. On the other hand, the EWB subscale
score signiﬁcantly increased immediately after C-ion RT, and
remained higher than the baseline level. The FWB score changed
very little during 60 months.
In the group with C-ion RT in combination with ADT, signiﬁ-
cant decreases were observed in FACT-G, FACT-P and TOI scores
at 12 months compared with those of the group without ADT;
however, at 36 and 60 months after C-ion RT, no signiﬁcant
decrease was observed in any scores between the two groups
(Fig. 2a and supplementary data).
Some kind of relapse was observed in 42 subjects, who had BF
and/or local recurrence, lymph node metastasis or distant metasta-
sis. The FACT-G, FACT-P and TOI scores in the group with
some kind of relapse were lower than those in the group without
any relapse, although the difference was of only borderline signiﬁ-
cance (P value = 0.06–0.10) (Fig. 2b and supplementary data).
The EWB score in the group with some kind of relapse was signiﬁ-
cantly decreased at 36 months and 60 months after C-ion RT
(data not shown). In this study, late adverse events were assessed
according to the RTOG/EORTC late morbidity criteria. Except
for one subject with Grade 3 genitourinary (GU) morbidity, no
severe late adverse events were observed at any assessment time
point. At 12, 36 and 60 months after C-ion RT, incidents of
Grade 1 or worse late adverse events were observed in 61 (15%),
132 (32%) and 89 (21%) patients, respectively (Table 4). The
FACT-P and TOI scores in the group with late morbidities were sig-
niﬁcantly lower than those in the group without late morbidities at
12, 36 and 60 months after C-ion RT (Fig. 2c and supplementary
data).
Table 2. Submission rate of the HRQOL questionnaire and response compliance rate
Before C-ion RT After C-ion RT
1 month 12 months 36 months 60 months
Number of living participants 417 417 416 402 394
Number of responses 401 389 402 386 365
% of responses of living participants 96.2 93.3 96.6 96.0 92.6
No. of available data for FACT-G 390 379 387 372 345
No. of available data for FACT-P 385 372 384 370 342
No. of available data for TOI 387 375 388 374 345
HRQOL = health-related quality of life, C-ion RT = carbon ion radiotherapy.
Table 1. Participant characteristics
Median age (range) 69 years (47–92)
Median PSA (range) 14.0 ng/ml (2.1–260)
No. of patients (%)
T Stage (UICC 1997)
≤T1c 109 (26.1)
T2a 87 (20.9)
T2b 81 (19.4)
T3a–b 140 (33.6)
Gleason Score
≤6 119 (28.5)
7 183 (43.9)
≥8 115 (27.6)
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DISCUSSION
In this study, we showed 5-year prospective follow-up results using
a QOL questionnaire after carbon ion radiotherapy. The FACT-P
and TOI scores decreased immediately after C-ion RT, but
returned to near-baseline levels at 12 months. The FACT-G score
showed a gradual and continual decrease after C-ion RT. The
FACT-P and FACT-G scores were signiﬁcantly lower than the
baseline level, even at 60 months after C-ion RT, but the absolute
change was only about 2 points. It is thought that the cause for
decreases in the FACT-P and FACT-G scores was the decrease of
the SFWB scores. The SFWB scores at 12–60 months in the pre-
sent study remained signiﬁcantly lower than those of the baseline.
Fujimoto et al. indicated culture-speciﬁc QOL issues for the
FACT-G questionnaire for Japanese lung cancer patients [17].
The reason why SFWB was decreasing after C-ion RT is poten-
tially cross-cultural issues, but it is still unknown. The TOI score,
not including SFWB and EWB, returned to near-baseline levels at
12 months.
Lee et al. carried out a prospective longitudinal study to analyze
the HRQOL assessment, using FACT questionnaires for up to
12 months after external beam radiotherapy, radical prostatectomy
or interstitial brachytherapy for prostate cancer. The FACT-P score
decreased at 1 month, but returned to baseline levels at 12 months
[18]. This study did not randomize the participants to a particular
treatment; however, the HRQOL decline reported by patients in
the EBRT group was smaller in magnitude than those in the prosta-
tectomy or brachytherapy group.
Recently, some prospective, long-term follow-up results in pros-
tate cancer patients were published. King et al. reported data using
the Expanded Prostate Cancer Index Composite (EPIC) instrument
in patients receiving stereotactic body radiation therapy. In their
study, transient decline in urinary/bowel domains within 3 months
returned to baseline or better within 6 months and remained.
Sexual QOL decline was predominantly observed within 9 months
and was not altered by androgen deprivation or age [19].
Hoskin et al. reported that QOL scores were maintained over a
10.5-year follow-up in prostate cancer patients randomized to
EBRT alone or with an HDR brachytherapy boost [20]. There was
no evidence that QOL deteriorated with increasing follow-up time
in any of the four FACT domains. They also reported that mean
FACT scores were signiﬁcantly lower in patients with moderate to
severe genitourinary morbidity than those free of morbidity.
In the present study, the presence of ≥G1 adverse events and
biochemical failure worsened the scores. On the other hand, the
decreases in QOL scores in patients with biochemical failure were
not statistically signiﬁcant. Possible reasons were the small number
of BF cases, or the use of salvage therapies. In addition, medication
may also affect the incidence rate of late adverse effects; however,
there is no restriction about medication for late toxicities or salvage
therapy for recurrent disease in our protocol.
Missing data would result in a signiﬁcant overestimation. It is
suggested that the longer the investigation period lasts, the more
difﬁcult it is to obtain necessary responses for a proper analysis. In
this study, the response rate was ~95% at all assessment time-
points. We considered that the number of missing data was small,
so we handled incomplete returns according to the Functional
Assessment of Chronic Illness Therapy (FACIT) guidelines. At
60 months after treatment, The FACT-G, FACT-P and TOI scores
in the group with any relapse seemed to be recovered; however, the
two patients with the lowest scores died in this period.
ADT is now commonly used for prostate cancer patients with
intermediate or high risk. ADT is known to adversely affect quality
of life, due to various symptoms including sexual dysfunction,
increased fatigue, and metabolic syndrome [21].
Sanda et al. reported long-lasting symptoms up to 2 years, des-
pite termination of ADT in patients receiving EBRT [22]. In the
Table 3. Mean (standard deviation) of scores of the individual subdomains, FACT-P, FACT-G, and TOI obtained from all of
the 417 subjects
Subdomains (full mark) Formula Before C-ion
RT
After C-ion RT
1 month 12 months 36 months 60 months
Physical well-being (28) (1) 25.1 (3.2) 24.4* (3.3) 24.6 (3.5) 25.1 (4.0) 25.3 (4.1)
Social/Family well-being (24) (2) 18.8 (5.5) 18.6 (5.7) 16.8* (6.4) 16.3* (6.5) 15.8* (6.9)
Emotional well-being (24) (3) 18.8 (4.0) 19.8* (3.7) 19.6* (3.7) 19.5* (3.9) 20.0* (3.5)
Functional well-being (24) (4) 21.3 (5.3) 20.8 (5.4) 21.6 (5.6) 21.4 (5.8) 21.0 (6.4)
Prostate cancer subscale (48) (5) 35.3 (6.2) 32.5* (6.4) 34.1* (6.5) 34.8 (6.9) 34.7 (7.2)
Index (full mark)
FACT-G (100) (1 + 2 + 3 + 4) 84.2 (12.6) 83.7 (12.9) 82.6* (13.7) 82.4* (14.3) 82.7* (15.0)
FACT-P (148) (1 + 2 + 3 + 4 + 5) 119.5 (16.9) 116.2* (17.1) 116.9* (18.4) 117.5* (19.3) 117.6* (20.2)
TOI (100) (1 + 4 + 5) 81.8 (12.0) 77.8* (12.1) 80.3 (13.0) 81.6 (13.7) 81.4 (14.6)
FACT-G = Functional Assessment of Cancer Therapy-General, FACT-P = Functional Assessment of Cancer Therapy for Prostate Cancer Patients, TOI = Trial
Outcome Index, C-ion RT = carbon ion radiotherapy. Asterisk indicates signiﬁcant changes in comparison with the corresponding baseline scores.
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present study, FACT-G, FACT-P and TOI scores in patients with
ADT were lower than those of patients without ADT, but signiﬁ-
cant decreases were observed at only 12 months after treatment.
Symptoms due to ADT may show improvement over a longer-term
follow-up period.
Our data were similar to those of other reports; however, it is
impossible to directly compare results with the present study
because of the use of different questionnaires or different treatment
modalities. In our Phase II study protocol, which was made in 1999,
the FACT questionnaire was selected since it was one of the most
reliable system in HRQOL assessment at that time. Randomized
trials remain the surest way of proving the utility of a new modality
such as carbon ion radiotherapy. However, particle therapy for pros-
tate cancer is not covered by the national health insurance system at
this time, so it would be very difﬁcult to compare C-ion RT with
other treatment modalities.
From a longitudinal prospective study with a large number of
patients, reliable data about HRQOL after C-ion RT for prostate
Fig. 2. (a) Comparison of changes of QOL scores (TOI)
between C-ion RT alone and in combination with ADT.
(b) Comparison of changes of QOL scores (TOI) between
the groups with and without biochemical failure (BF).
(c) Comparison of changes of QOL scores (TOI) between
patients in whom no adverse events observed and those in
whom ≥Grade 1 late adverse events were observed.
Asterisk indicates signiﬁcant difference between two
groups.
Fig. 1. Changes of QOL scores (FACT-G and TOI).
Asterisk indicates signiﬁcant change in comparison with
baseline scores.
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cancer were obtained. The pattern of HRQOL change after C-ion
RT was similar to those of other treatment modalities. QOL scores
by FACT questionnaires were maintained at roughly the same levels
during a long-term follow-up period. We believe that QOL assess-
ment provides additional useful information for the treatment of
prostate cancer patients.
SUPPLEMENTARY DATA
Supplementary data are available at Journal of Radiation Research
online.
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